Physician profile

Donna Leet

San Francisco, CA

NPI 1750918934

$428.04

in general payments reported to CMS, 2019-2025

4 companies · $398 in 2025

The $398 reported for 2025 was more than what 75% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$428.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Conmed Corporation $166.40 2025 Conmed Hemostasis, Conmed Biliary
Genzyme Corporation $144.45 2025
Olympus America INC. $87.01 2025 Endoclot Phs, Single Use Electrosurgical Knife Kd-655, Single Use Aspiration Needle Na-U200h
Medtronic, INC. $30.18 2024 Bravo

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Donna Leet

$428.04

in general payments reported 2019-2025

Years
2024-2025
Top company
Conmed Corporation
Context
The $398 reported for 2025 was more than what 75% of providers received nationally.

https://glasscript.com/doctor/11694248/donna-leet

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.